Our primary objectives.
Bionature focuses on the development of novel, proprietary, blood-brain barrier permeable small molecules for the treatment of neuroinflammatory and neurodegenerative diseases, such as diabetic retinopathy, demyelination and multiple sclerosis, Parkinson and Alzheimer diseases. Bionature's team has discovered that its synthetic small molecules interact with the receptors of the endogenous neurotrophins, nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) and are therefore referred to as "microneurotrophins."
Microneurotrophins have been shown to be very effective in preventing and reversing the demyelination and neuronal degeneration observed in the cuprizone mouse model of demyelination and multiple sclerosis (MS) and in preventing apoptosis in animal models of diabetic retinal degeneration, Alzheimer and Parkinson diseases. They are also strong inducers of neurogenesis ex vivo and in vivo, propagating the formation of fresh neural tissue.
Learn moreWhere we are today
Bionature owns a robust intellectual property portfolio in the field that includes patents covering the composition of matter of newly synthesised small molecules and the use of these molecules for the treatment of human pathologies. The Company has completed pre-clinical proof of efficacy studies in various animal models and has established the safety profile of its drug candidate molecules.
Learn moreOpportunities
It is currently in the process of exploring opportunities for further pre-clinical development that could lead to Phase I/II studies by the end of 2022. Bionature's novel multi-dynamic (anti-apoptotic, anti-neuroinflammatory, neurogenic) lead molecules hold significant promise to become first in class therapeutic agents of tremendous clinical importance and value.
Learn more